Table 2.

Associations of plasma metabolites with change in eGFR in the Nutrition and Health of Aging Population in China study

MetaboliteChange in eGFR (ml/min per 1.73 m2 per year)Incident Reduced eGFR
β (95% Confidence Interval)P ValueRelative Risk (95% Confidence Interval)P Value
Cysteine−0.25 (−0.33 to −0.17)2.7E−091.25 (1.13 to 1.39)3.5E−05a
C3DC−0.19 (−0.27 to −0.11)5.8E−061.18 (1.06 to 1.32)2.6E−03a
C10−0.17 (−0.25 to −0.10)1.6E−051.20 (1.07 to 1.33)1.1E−03a
C20−0.18 (−0.26 to −0.09)3.8E−051.12 (1.01 to 1.24)3.3E−02
C14:1OH−0.17 (−0.25 to −0.09)4.5E−051.17 (1.06 to 1.29)1.9E−03a
C18−0.17 (−0.26 to −0.09)5.6E−051.17 (1.06 to 1.30)2.0E−03a
C18:2−0.17 (−0.25 to −0.09)1.0E−041.18 (1.07 to 1.30)6.0E−04a
C16:2−0.16 (−0.24 to −0.07)2.0E−041.16 (1.05 to 1.28)4.1E−03
Phenylalanine−0.16 (−0.24 to −0.07)2.0E−041.16 (1.05 to 1.29)4.0E−03
Glutamine−0.15 (−0.23 to −0.07)3.0E−041.14 (1.02 to 1.27)1.6E−02
C8−0.14 (−0.22 to −0.06)4.0E−041.15 (1.03 to 1.27)1.1E−02
C20:4−0.15 (−0.23 to −0.07)4.0E−041.19 (1.08 to 1.31)4.0E−04a
C5OH−0.15 (−0.23 to −0.06)4.0E−041.10 (1.01 to 1.21)3.7E−02
  • Data are annual change in eGFR or relative risk per SD increase in metabolite concentration, after adjustment for age, sex, region (Beijing/Shanghai), residence (urban/rural), education, current smoking, current drinking, physical activity, body mass index, lipid-lowering medication use, HDL, LDL, cardiovascular disease, hypertension, type 2 diabetes, and eGFR at baseline. Only metabolites associated with annual eGFR change after Bonferroni correction for multiple testing of the 56 metabolites (P<8.9E−04) are shown.

  • a Significant association with incident reduced eGFR with P<3.8E−03 after Bonferroni correction for multiple testing of the 13 metabolites associated with annual eGFR change.